[Age-related macular degeneration and antivascular endothelial growth factor: a review].
We provide an overview of new anti-VEGF treatments for exudative age-related macular degeneration. We reviewed the current literature on this topic (including randomized controlled trials, nonrandomized and noncontrolled trials, and case reports). The efficacy and safety of anti-VEGF therapies for AMD are reported. We discuss combined therapy approaches, treatment frequency, and emerging therapies for exudative AMD. Therapies that target VEGF greatly improve treatment for exudative AMD. However, many questions are still being debated.
Fajnkuchen
F
F
Centre Ophtalmologique d'Imagerie et de Laser, Paris. franck.fajnkuchen@avc.aphp.fr
Cohen
S-Y
SY
D000368:Aged; D000375:Aging / Q000502:physiology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A